EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs)

Wenzhong Yan iD, Mingshun Feng, Kexin Yang, Chengcheng Yu, Wenxin Zhang, Junjun Liu, Chengying Xie, Jianjun Cheng iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c03481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Wenzhong Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: iHuman Institute, ShanghaiTech University, Shanghai 201210, China. Hauptthemen laut MEDLINE: Receptor, Adenosine A2A, Histone Deacetylases, Histone Deacetylase Inhibitors, Adenosine A2 Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Shanghai Municipal People's Government, ShanghaiTech University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent research has identified that adenosine A2A receptor (A2AR) antagonists are promising agents for cancer immunotherapy. However, their limited efficacy as monotherapies remains an unresolved challenge. A2AR/HDAC dual-targeting compounds have demonstrated more potent antitumor efficacy and warrant further investigation. To further improve the drug-like properties of such compounds in our previous work, a pharmacokinetics-driven structural optimization campaign was undertaken and led to the identification of compound 13t (IHCH-3185), which exhibited a markedly enhanced pharmacokinetic profile in mice. Furthermore, 13t retained potent target engagement (A2AR Ki = 7.6 nM, HDAC1 IC50 = 102.9 nM) and demonstrated broad-spectrum antiproliferative activity in vitro. Oral administration of 13t significantly inhibited CT26 and MC38 tumor growth in mice with tumor growth inhibition rates of 68.5% and 71.1%, respectively. This robust activity was attributed to a dual mechanism combining immune stimulation and direct antiproliferative effects. These results make 13t a promising cancer immunotherapy drug candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Adenosine A2AHistone DeacetylasesHistone Deacetylase InhibitorsAdenosine A2 Receptor AntagonistsAntineoplastic AgentsAnimalsHumansMiceImmunotherapyCell ProliferationCell Line, TumorStructure-Activity Relationship

Substanzen

Receptor, Adenosine A2AHistone DeacetylasesHistone Deacetylase InhibitorsAdenosine A2 Receptor AntagonistsAntineoplastic Agents

Autor:innen und Institutionen

  • iHuman Institute, ShanghaiTech University, Shanghai 201210, China.
  • Lingang Laboratory, Shanghai 200031, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.

ORCID-Profile: Wenzhong Yan, Jianjun Cheng

Förderung

  • Shanghai Municipal People's Government
  • ShanghaiTech University
  • National Natural Science Foundation of China

Zitieren

APA

Yan, W., Feng, M., Yang, K., Yu, C., Zhang, W., Liu, J., Xie, C., & Cheng, J. (2026). Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03481

Vancouver

Yan W, Feng M, Yang K, Yu C, Zhang W, Liu J, et al. Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs). Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03481

BibTeX
@article{Yan2026,
  author = {Yan, Wenzhong and Feng, Mingshun and Yang, Kexin and Yu, Chengcheng and Zhang, Wenxin and Liu, Junjun and Xie, Chengying and Cheng, Jianjun},
  title = {Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs)},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c03481}
}
Kostenlos starten →